FOLH1 and prostate carcinoma: Our study further corroborates these findings, indicating that SUVmax derived from 68Ga-PSMA-11 PET/MR, with an optimal cut-off of 7.67, can effectively evaluate Ki-67 expression in prostate cancer patients.